Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand,
BioDrugs. 2013 Oct;27(5):525-31. doi: 10.1007/s40259-013-0061-2.
Regorafenib (Stivarga(®)), a new inhibitor of multiple kinases, is indicated as third-line treatment in patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib and sunitinib in the USA. In a phase III trial in patients with progressive GIST after failure of standard therapies, regorafenib plus best supportive care increased median progression-free survival by >5-fold relative to best supportive care alone. Although regorafenib is associated with several specific drug-related adverse events, it is reasonably well tolerated if recommendations for dose modifications (i.e. treatment interruption, dose reductions and/or permanent treatment discontinuation based on tolerability) and other precautions are followed.
瑞戈非尼（Stivarga(®)）是一种多激酶抑制剂，在美国被批准用于治疗先前接受过伊马替尼和舒尼替尼治疗的局部晚期、不可切除或转移性胃肠道间质瘤（GIST）患者的三线治疗药物。在一项针对标准治疗失败后进展性 GIST 患者的 III 期临床试验中，瑞戈非尼联合最佳支持治疗相对于单独最佳支持治疗使中位无进展生存期延长了 5 倍以上。虽然瑞戈非尼与一些特定的药物相关不良反应有关，但如果遵循剂量调整（即基于耐受性的治疗中断、剂量减少和/或永久停药）和其他预防措施的建议，该药具有较好的耐受性。
